Work participation in patients with axSPA Patients w/ axSpA often have increased absence from work as well as reduced productivity at work, which can lead to wider economic & social burden. Dr. Dey (@DrMiniDey) discusses abstracts from #ACR21. https://t.co/eAMLPR2zoT https://t.co/NuIajGa7gx

• https://bit.ly/3BTBqXG

RHEKISS registry: SpA pts on bDMARDs at conception are NOT at inc. risk for adverse pregnancy outcomes. Discontinuation of bDMARDs after conception is assoc'd w/ inc. dz activity during/after pregnancy & flare risk. Abs 1730 #ACR21 #RheumNow @RheumNow https://t.co/b2wI9GZios https://t.co/wsuvv3hF0v

• Disease Activity and Outcome in Pregnancies of Patients with SpA - Data from th…

Post hoc analysis of pooled data from 19 clin trials on SEC & CV risk & systemic #inflammation in PsO, PsA, AS 📌Traditional CV parameters remained stable on all SEC treated grps 📌SEC sig. ⬇hsCRP & NLR @RheumNow #ACR21 abs1835 https://t.co/iCaGFbXNXn

French study shows more than 75% of RA/SpA pregnancies resulted in a live-birth, BUT 50% of pts had at least one unfavorable pregnancy outcome! However, miscarriage prevalence lower than in reported literature. Abs 1724 #ACR21 #RheumNow @RheumNow https://t.co/64PspIKPTu https://t.co/LyfHVARAgd

• More Than 50% of Women with Chronic Rheumatic Inflammatory Diseases Present an …

SERENA interim analysis on interruption of secukinumab in AS and PsA 🔹>=16 wks of Rx before interruption of >= 3 mo. 🔹75-80% of pts reinitiated w/o loading phase 🔹AS: BASDAI, PGA stable 🔹PsA: SJC, TJC returned to Rx baseline https://t.co/3G6rVW8TPv #ACR21 Abst#1361 @RheumNow

• Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patien…

Have you heard of pSpA? (Peripheral) pSpA: distinct clinical phenotype w/ intermediate features between pure PsA & pure axSpA but w/ a higher disease burden compared to both diseases, & lower use of b-DMARDs. Abs 1787 #ACR21 #ACRbest #RheumNow @RheumNow https://t.co/Wsysm7A0Y3 https://t.co/rwQ8ukBEDq

• What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden:…

5 yr multinational PROOF study - enrolled 1612 axSpA pts enrolled (65% xray+ axSpA; 35% nr-axSpA) nraxSpA had more enthesitis, PSO IBD. Over time, more TNFi use (less NSAIDs) w/ less disease activity #ACR21 Abst #0363 https://t.co/5DdDlCjq9h (Graph: NSAID use over time) https://t.co/5JE69vTIy9

• https://bit.ly/2Ytz18g

Pregnant pts w/ PsA, but not AxSpA, at increased risk of pre-eclampsia. In RA pregnancies, pre-eclampsia risk increases w/ dz severity prior/during pregnancy. We need to discuss potential risks w/ pts and OB team. Abs 1722 #ACR21 #RheumNow @RheumNow https://t.co/yeQmNAZ1jV https://t.co/cBfeVKQHfr

• Risk of Pre-eclampsia and Impact of Disease Activity and Anti-rheumatic Treatme…

Upadacitinib showed similar efficacy in AS pts compared to PsA pts with axial involvement ⭐️PsA pt w/ axial involvement and AS pts with differences in baseline characteristics #ACR21 @RheumNow Abs#1802 https://t.co/QvyayelBYU https://t.co/50dNQm30vf

• https://bit.ly/3bWiQmZ

Fr AQUILA study: #Uveitis status in AS or PsA pts given SEC 👁‍🗨3 pts w/o uveitis at BL developed new onset uveitis during study 👁‍🗨Most pts w/uveitis at BL - status remained unchanged or improved 👁‍🗨SEC did not ⬆ risk of uveitis @RheumNow #ACR21 abs1738 https://t.co/IGUpgXBLvt